Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
https://kalkinemedia.com/resources/assets/public/img/flags/au.png AUS
https://kalkinemedia.com/resources/assets/public/img/flags/nz.png NZ
https://kalkinemedia.com/resources/assets/public/img/flags/uk.png UK
https://kalkinemedia.com/resources/assets/public/img/flags/ca.png CA
https://kalkinemedia.com/resources/assets/public/img/flags/us.png USA
https://kalkinemedia.com/resources/assets/public/img/flags/fr.png FRA
https://kalkinemedia.com/resources/assets/public/img/flags/de.png GER
https://kalkinemedia.com/resources/assets/public/img/flags/es.png ESP
https://kalkinemedia.com/resources/assets/public/img/flags/it.png ITA
https://kalkinemedia.com/resources/assets/public/img/flags/nl.png NLD
https://kalkinemedia.com/resources/assets/public/img/flags/pt.png PRT
https://kalkinemedia.com/resources/assets/public/img/flags/se.png SWE
https://kalkinemedia.com/resources/assets/public/img/flags/gr.png GRC
https://kalkinemedia.com/resources/assets/public/img/flags/in.png IND
https://kalkinemedia.com/resources/assets/public/img/flags/pl.png POL
https://kalkinemedia.com/resources/assets/public/img/flags/br.png BRA
https://kalkinemedia.com/resources/assets/public/img/flags/za.png ZAF
https://kalkinemedia.com/resources/assets/public/img/flags/ru.png RUS
https://kalkinemedia.com/resources/assets/public/img/flags/cn.png CHN
https://kalkinemedia.com/resources/assets/public/img/flags/ae.png UAE
Kalkine Media ASX Share Market News & Research

Why Aridis Pharmaceuticals (ARDS) soared on Thursday?

January 27, 2022 06:22 PM CET | By Rupam Roy
Why Aridis Pharmaceuticals (ARDS) soared on Thursday?
Image source: PopTika,Shutterstock,shutterstock

Recent News

thumbnail

Litigation Funding from a European Perspective

thumbnail

leagend Unveils TC810 Automotive Thermal Imaging Night Vision System t...

thumbnail

Litigation Funding: Study Commissioned by the European Commission Publ...

thumbnail

L’ESTATE ITALIANA DI SAMMONTANA, GELATI ALL’ITALIANA, SI ANIMA AL PORT...

Highlights

  • Aridis said it received funding from Bill & Melinda Gates Foundation.

  • The funds will be used to evaluate inhaled monoclonal antibodies.

  • The ARDS stock returned over 30% gains in the past five days.

The stocks of Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) caught the eyes of investors on Thursday after the company said it received funding from the Bill & Melinda Gates Foundation to evaluate the application of inhaled monoclonal antibodies in patients suffering from influenza and covid.

The Los Gatos, California-based biopharmaceutical firm develops targeted immunotherapy using human monoclonal antibodies for treating severe infections.

Also Read: Top five cloud computing stocks to explore in 2022

On Thursday, Aridis said it received US$1.9 million from the Gates foundation to evaluate the application of its cost-effective inhaled formulation technology.

The monoclonal antibodies (mAbs) are used for treating patients suffering from influenza and SARS-CoV2 in low and middle-income countries.

The antibodies are created using a novel, spirulina-based technology platform developed by Lumen Bioscience, a funding collaborator for the project.

Lumen’s platform can produce therapeutic proteins at a fraction of the cost of conventional mammalian cell line technologies.

Also Read: Why DIA (DIA) token climbed over 53% today?

Aridis Pharmaceuticals soars over 25% after receiving funding from the Gates Foundation

Also Read: BitTorrent surges 9% as exchanges start accepting BTT token migration

Aridis Pharmaceuticals Inc. (NASDAQ:ARDS): Stock performance, financials

The shares of ARDS were priced at US$2.19 at 9:18 am ET on January 27, up 25.86% from its previous close. Over the past five days, its prices surged 30.83%. The firm has a market cap of US$24.45 million, its forward P/E one year is -0.47, and the EPS is US$-3.79.

Also Read: Osmosis (OSMO) among top 10 chains by TVL - Know more

The ARDS stock saw the highest price of US$8.47 and the lowest price of US$1.13 in the last 52 weeks. Its trading volume on January 26 was 1,468,205.

The company reported revenue of US$515,000 in Q3, FY21. It reported zero revenue in the third quarter of the previous year. In addition, its net loss was US$21.00 million against a loss of US$5.78 million in the comparable quarter of the last year.

Also Read: Top ETF trends to watch in 2022

Bottomline

The US$1.9-million award will fund the preclinical development of stabilized liquid aerosols and inhalable dry powders. They contain anti-influenza and anti-SARS-CoV2 monoclonal antibodies created from spirulina algae.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles